Novo Nordisk's Oral Semaglutide: A Game-Changer for Obesity Therapeutics and Investor Value?

Novo Nordisk's semaglutide-based therapies have dominated the obesity and diabetes therapeutics market in 2025, with combined sales of Ozempic, Rybelsus, and Wegovy reaching USD 16.7 billion in the first half of the year. This figure unseated MSD's KEYTRUDA® as the world's top-selling drug, driven by Ozempic's USD 9.6 billion in revenue and Wegovy's 78% year-over-year growth to USD 5.5 billion Novo Nordisk H1 2025: Semaglutide Unseats Keytruda from Top ...^[2]. Historically, Novo Nordisk's stock has shown a positive response to earnings announcements, with a 15-day average return of 5.4% compared to a 0.56% benchmark return, according to a backtest of earnings events from 2022 to 2025 . However, the company has tempered expectations for the full year, citing slower U.S. adoption of Wegovy and Ozempic and intensifying competition Novo Nordisk H1 2025: Semaglutide Unseats Keytruda from Top ...^[2].

The introduction of an oral formulation of semaglutide—marketed as “Wegovy® in a pill”—could redefine the landscape. Clinical trials published in the New England Journal of Medicine demonstrated that the 25 mg oral dose achieved a mean weight loss of 16.6% over 64 weeks, compared to 2.7% with placebo, with 34.4% of participants losing 20% or more of their body weight Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1]. These results mirror those of the injectable Wegovy, while offering a more patient-friendly delivery method. Novo Nordisk submitted a New Drug Application (NDA) for the oral formulation in February 2025, with an FDA decision expected by year-end Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

The Unmet Need and Market Potential

Despite semaglutide's success, adoption of obesity medications in the U.S. remains dismally low. Less than 2% of individuals with obesity currently receive pharmacologic treatment, a gap Novo Nordisk attributes to the inconvenience of injectables and limited patient awareness Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1]. Martin Holst Lange, a senior executive at the company, emphasized that an oral option could boost adherence and willingness to start GLP-1 therapy Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

The OASIS 4 phase 3 trial further validated this potential. Participants on oral semaglutide lost an average of 13.6% of their body weight under real-world adherence conditions, with 29.7% achieving ≥20% weight loss Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1]. Safety profiles were consistent with the injectable version, with gastrointestinal side effects being the most common adverse events Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1]. If approved, Novo Nordisk plans to manufacture the drug in the U.S., ensuring supply to meet anticipated demand Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

Challenges and Investor Considerations

While the oral formulation holds promise, several factors could temper its impact. First, the U.S. market's sluggish adoption of Wegovy and Ozempic—despite their efficacy—suggests that cost, insurance coverage, and patient preferences may persist as barriers. Some patients still favor the once-weekly injectable format over a daily pill Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1]. Second, newer GLP-1 agonists like Eli Lilly's tirzepatide have shown superior weight loss outcomes in trials, raising questions about whether oral semaglutide can compete on efficacy Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

However, the oral option addresses a critical unmet need: accessibility. For patients who find injections inconvenient or stigmatizing, a pill could democratize access to GLP-1 therapies. Analysts at Medscape note that oral semaglutide could serve as a “gateway” treatment, encouraging broader adoption of the class and potentially expanding the market for more advanced therapies Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

Redefining GLP-1 Demand and Investor Value

The obesity therapeutics market is projected to grow substantially as GLP-1 agonists become mainstays in weight management. Novo Nordisk's dominance in this space is underpinned by its first-mover advantage with semaglutide, but the oral formulation could further entrench its leadership. If approved, the drug could capture a significant share of the 70 million U.S. adults with obesity who are currently untreated Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*)^[1].

For investors, the key risks lie in regulatory delays, pricing pressures, and competition. Novo Nordisk's revised full-year forecast highlights the volatility of the U.S. market, where reimbursement hurdles and generic alternatives could erode margins. Conversely, the company's robust pipeline and manufacturing capacity position it to capitalize on long-term demand.

Conclusion

Novo Nordisk's oral semaglutide represents a pivotal innovation in obesity care, with the potential to expand treatment access and redefine GLP-1 adoption. While challenges remain, the drug's clinical efficacy and patient-centric design align with the growing demand for sustainable weight management solutions. For investors, the approval and commercialization of this oral formulation could unlock significant value—provided Novo Nordisk navigates the competitive and regulatory landscape effectively.